Astellas receives US approval for tacrolimusZenopaThe drug will be known as Astagraf XL in the US and is intended for use among patients with mycophenolate mofetil and corticosteroids, both with and without basiliximab induction. Approval was granted b…
|
Biogen Idec’s long-acting beta interferon moves ahead in MS
PMLiVE Biogen Idec’s also sells Tysabri (natalizumab) for MS, which is expected to remain an important treatment option for some patients, and is also bringing a new anti-CD-25 antibody called daclizumab through late-stage development in partnership with Idec. |
|
아스텔라스 면역억제제 ‘아스타그랍’ 승인장기이식 거부반응 효과 …임상 3상 시험 …
의약뉴스 아스타그랍은 1일 1회 복용하는 경구약으로 바실릭시맙(basiliximab)을 포함하거나 혹은 포함하지 않고 마이코페노레이트 모페틸(mycophenolate mofetil)과 코르티코스테로이드(corticosteroids) 약물과 병용해 이식거부반응을 예방한다. 이번 승인은 1093명의 환자 … |
MedPage Today |
U.S. Launch of Astellas’ Astagraf XL – Analyst Blog
NASDAQ … received approval for Astagraf XL (tacrolimus extended-release capsules) in the U.S. for the prevention of organ rejection in patients receiving a kidney transplant with mycophenolate mofetil (MMF) and corticosteroids, with or without basiliximab … Long-Release Tacrolimus Wins FDA NodMedPage Today New Treatment Option for Kidney Transplant RecipientsMonthly Prescribing Reference FDA approves Astellas once-daily organ rejection drugPharmaTimes Genetic Engineering News –NephrologyNews.com –The Pharma Letter all 8 news articles » |
New Treatment Option for Kidney Transplant RecipientsMonthly Prescribing ReferenceAstagraf XL (tacrolimus extended-release capsules; Astellas) has been approved for the prophylaxis of organ rejection in patients receiving a kidney transplant with mycop…
MedPage TodayLong-Release Tacrolimus Wins FDA NodMedPage TodaySpecific indications for the extended-release form are for prophylaxis of graft rejection in kidney transplant patients also receiving mycophenolate mofetil and corticosteroids, with or with…
MedPage TodayU.S. Launch of Astellas Astagraf XLZacks.com… received approval for Astagraf XL (tacrolimus extended-release capsules) in the U.S. for the prevention of organ rejection in patients receiving a kidney transplant with mycophenolate mofetil…
Astellas Announces FDA Approval of ASTAGRAF XLTM (tacrolimus extended …PipelineReview.com (press release)… Administration (FDA) has approved ASTAGRAF XLTM (tacrolimus extended-release capsules) for the prophylaxis of organ rejection in patients rec…
|
Astellas: FDA OKs Kidney Transplant Rejection Drug
Genetic Engineering News … announced it has received FDA approval for Astragraf XL™ (tacrolimus extended-release capsules) for the prophylaxis of kidney rejection in patients receiving a transplant with mycophenolate mofetil and corticosteroids, with or without basiliximab … |
|
FDA approves Astellas once-daily organ rejection drug
PharmaTimes The thumbs-up is for the once-daily oral drug to be used with a regimen that includes treatment with with mycophenolate mofetil and corticosteroids, with or without basiliximab induction. Sef Kurstjens, chief medical officer at Astellas’ US unit, said … Astellas reports FDA approval of anti-rejection drugNephrologyNews.com Astellas Pharma secures US FDA approval for ASTAGRAF XLPharmaceutical Business Review |